-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Initiates Coverage On Day One Biopharmaceutical with Buy Rating, Announces Price Target of $34

Benzinga·01/13/2026 19:14:57
Listen to the news
TD Cowen analyst Tara Bancroft initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy rating and announces Price Target of $34.